Previously, starting dose was IV-only in a clinical setting, with transition to IV/subcutaneous maintenance after 18 months
Safety and Side Effects Like all GLP-1 medications, both liraglutide and semaglutide can cause some gastrointestinal distress including nausea, diarrhea, vomiting, reflux and constipation
Common Community-Reported Side Effects Nausea, diarrhea, constipation, vomiting (retatrutide-driven, dose-dependent)
For more information on GLP-1 therapies, see the European Medicines Agencys overview of Ozempic
It produces glucose through gluconeogenesis, building it from amino acids, lactate, and glycerol, none of which require you to eat carbohydrates first
10 , BC08BC10 (2016)